Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 504, Issue 1-2, Pages 110-116Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijpharm.2016.03.022
Keywords
Magnetite nanoparticles; Magnetic nanoparticle (MNP); Methotrexate (MTX); Anti-cancer; Drug delivery; MCF-7
Categories
Funding
- Research Council of Shiraz University of Medical Sciences [94-01-36-10111]
Ask authors/readers for more resources
In this work, novel hydroxyl-modified magnetite nanocarriers are introduced as efficient host for methotrexate conjugation. The modification was based on the Micheal type addition reaction between tris(hydroxymethyl) aminomethane and acrylamidopropyl functionalized, silica-coated magnetite nanoparticle. The chemical structure characterization was carried out by FT-IR and the organic content was determined by CHN analysis. The topography was studied by SEM, TEM, AFM. DLS was performed to show particles' mean diameter. Furthermore, the magnetite properties of modified particles were evaluated by VSM and the crystallinity was proved by XRD. To illustrate the efficiency of the modified particles, the anti-cancer drug methotrexate was conjugated to hydroxyl groups through estric bond formation. The controlled release activity of established nanoparticles was evaluated in simulated cellular fluid. Later, the anti-cancer behavior of drug conjugated nanoparticles was evaluated in vitro in MCF-7 cell line which showed enhanced toxicity after 48 h. Conclusively, the modified nanoparticles have remarked as powerful carrier to be applied as an anti-cancer agent. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available